The early identification of aggressive forms of cancer is of high importance in treating
papillary thyroid cancer (PTC). Disease dissemination is a major factor influencing patient …

Objective There are many conflicting reports about the clinical implications of BRAF V600E
in papillary thyroid cancer (PTC). We investigated the associations between the extent of …

Simple Summary This study aimed to investigate the relationship between the allele
frequency (AF) of the BRAF V600E mutation and the histopathological features of papillary …

Papillary thyroid carcinoma (PTC) is the most common histological thyroid cancer,
accounting for approximately 80% of thyroid cancers. Although PTC is highly curable, some …

The aim of this study was to investigate the association between the BRAF V600E mutation
incidence and histopathologic prognostic risk factors for papillary thyroid carcinoma (PTC) …

The BRAF V600E mutation is the most common genetic alteration in thyroid cancer.
However, its clinicopathological significance and clonal mutation frequency remain unclear …

The aim of the present study was to investigate the prevalence of the BRAF V600E mutation
in papillary thyroid carcinoma (PTC) and to determine the correlation between this mutation …

Background: Papillary thyroid carcinoma (PTC) is the most common malignant thyroid
tumour. A common mutation of papillary thyroid carcinoma (PTC) is the somatic mutation of …

Purpose: Papillary thyroid carcinoma (PTC) is the most common thyroid malignancy. Most
PTC patients have a good prognosis. However, about 10% cases showed aggressive …

Context: BRAFV600E is considered a negative prognostic marker in papillary thyroid
carcinoma (PTC), but unexplained conflicting results are present in the literature. In light of …